Dr Jean-Jacques Kiladjian at ASH 2014: Efficacy of ruxolitinib by baseline spleen volume in polycythemia vera resistant to or intolerant of hydroxyureaa - 101271

Spotlight
Video

Dr Jean-Jacques Kiladjian at ASH 2014: Efficacy of ruxolitinib by baseline spleen volume in polycythemia vera resistant to or intolerant of hydroxyureaa

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jean-Jacques Kiladjian (Hôpital Saint-Louis & Université Paris Diderot, Paris, France) discusses a post-hoc analysis of the phase III RESPONSE trial, which compared ruxolitinib and best available therapy in patients with polycythaemia vera and splenomegaly who were intolerant of or resistant to hydroxyurea, to determine if treatment outcomes were influenced by baseline spleen volume.
Shared By : EMJ
Posted on : 01/09/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.